Objective: To review the literature regarding point-of-care (POC) cholesterol monitors and describe their role in pharmacy practice.
Data Sources: Primary articles were identified by a MEDLINE search (1966-May 2003); references cited in these articles provided additional resources.
Study Selection And Data Extraction: All of the articles identified from this search were reviewed, and all information deemed relevant was included.
Data Synthesis: Hyperlipidemia is a well-established risk factor for coronary artery disease, which is the leading cause of death in the US. The use of POC cholesterol monitors may help to improve the identification and management of this disease. Pharmacists may use many of these devices in their practice and are also in an ideal position to provide patient education on selection and use of these monitors and interpretation of the results.
Conclusions: The availability of POC cholesterol monitors has increased in recent years. Based on currently available data, these monitors are best suited for screening purposes and to assist in the management of hyperlipidemia. There is not enough evidence to support the notion that POC cholesterol monitors can replace laboratory or office monitoring. Their application in the diagnosis of hyperlipidemia is also currently limited.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1D269 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A non-enzymatic dual sensing approach for the detection of cholesterol in real samples using silk fiber functionalized phosphorene quantum dots.
Nanoscale
December 2024
Institute of Advanced Study in Science and Technology, Paschim Boragaon, Guwahati-35, Assam, India.
Reliable point-of-care (POC) detection of the specific biomarkers responsible for different diseases is crucial for health monitoring. For the routine detection of important biomarkers, rapid, precise, and cost-effective analytical techniques are more and more in demand. Cardiovascular diseases like hypertension, myocardial infarction, and stroke can occur due to high cholesterol levels.
View Article and Find Full Text PDFCommunity Pharmacists Identification of Gaps in Care - Statin Utilization for Primary Prevention.
J Pharm Pract
June 2024
Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM, USA.
Statins are a highly effective lipid-lowering therapy associated with significant reductions in atherosclerotic cardiovascular disease (ASCVD) events and death. Despite these benefits, statins are underutilized. Pharmacist-led interventions to increase statin prescribing are effective.
View Article and Find Full Text PDFPerformance evaluation of Barozen Lipid Plus for point-of-care testing of lipid profiles: a method comparison study.
J Yeungnam Med Sci
November 2023
Department of Family Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Article Synopsis
- A study evaluated the Barozen Lipid Plus, a point-of-care lipid analyzer, by comparing its measurements of total cholesterol, triglycerides, and HDL-C with those from a standard reference device.
- Blood samples were taken from 110 participants for analysis, and results indicated that over 95% of the measurements from Barozen Lipid Plus were within acceptable limits when compared to the reference device.
- Participant feedback highlighted high satisfaction with the convenience of the POC device, reinforcing its reliability for real-time lipid level monitoring in clinical settings.
Natural Indigenous Paper Substrates for Colorimetric Bioassays in Portable Analytical Systems: Sustainable Solutions from the Rain Forests to the Great Plains.
ACS Appl Mater Interfaces
October 2023
CF-UM-UP, Centro de Física das Universidades do Minho e Porto, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Point-of-care (POC) devices can provide inexpensive, practical, and expedited solutions for applications ranging from biomedicine to environmental monitoring. This work reports on the development of low-cost microfluidic substrates for POC systems suitable for analytical assays, while also satisfying the need for social and environmentally conscious practices regarding circular economy, waste reduction, and the use of local resources. Thus, an innovative greener process to extract cellulose from plants including abaca, cotton, kozo, linen, and sisal, originating from different places around the world, is developed, and then the corresponding paper substrates are obtained to serve as platforms for POC assays.
View Article and Find Full Text PDFProof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
J Clin Endocrinol Metab
November 2023
Department of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Context: Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED).
Objective: We report the first clinical studies of an FcRn inhibitor, batoclimab, in TED.
Design: Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!